Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 501–600 of 1,003
Zhang, Q., Wang, T., Geng, C., Zhang, Y., Zhang, J., Ning, Z., Jiang, Z., & Shenzhen Chipscreen Biosciences, S. 5. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.06.05 · Cited by 41
Hanif, M., Arshad, J. Z., Astin, J. W., Rana, Z., Zafar, A., Movassaghi, S., Leung, E. Y., Patel, K. D., Söhnel, T., Reynisson, J., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202005758 · Cited by 42
A p53/lnc‐Ip53 Negative Feedback Loop Regulates Tumor Growth and Chemoresistance
Zhang, L., Yang, J., Luo, Y., Liu, F., Yuan, Y., & Zhuang, S. (2020) · Advanced Science · doi:10.1002/advs.202001364 · Cited by 43
Guo, Z., Zhang, Z., Zhang, Y., Wang, G., Huang, Z., Zhang, Q., & Li, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113383 · Cited by 41
Sirous, H., Campiani, G., Calderone, V., & Brogi, S. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104808 · Cited by 40
Taha, T. Y., Aboukhatwa, S. M., Knopp, R. C., Ikegaki, N., Abdelkarim, H., Jayaprakash, N., Lu, Y., Neelarapu, R., Hanigan, T. W., Thatcher, G. R. J., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00126 · Cited by 44
Kitir, B., Maolanon, A. R., Ohm, R. G., Colaço, A. R., Fristrup, P., Madsen, A. S., & Olsen, C. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00725 · Cited by 38
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Zhang, S., Chen, Y., Tian, C., He, Y., Tian, Z., Wan, Y., & Liu, T. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200610174453 · Cited by 43
Li, X., Wang, J., Huo, F., & Yin, C. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215713 · Cited by 40
Substrate and Functional Diversity of Protein Lysine Post-translational Modifications
Hao, B., Chen, K., Zhai, L., Liu, M., Liu, B., & Tan, M. (2024) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzae019 · Cited by 47
Lan, X., Lu, G., Yuan, C., Mao, S., Jiang, W., Chen, Y., Jin, X., & Xia, Q. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2020-4 · Cited by 38
Wei, T.-T., Lin, Y., Chen, W., Luo, P., Lin, Y., Shun, C., Lin, Y.-H., Chen, J.-B., Chen, N.-W., Fang, J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.019 · Cited by 41
TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism
New, M. I., Sheikh, S., Bekheet, M., Olzscha, H., Thézénas, M., Care, M. A., Fotheringham, S. A., Tooze, R. M., Kessler, B. M., & Thangue, N. B. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0504 · Cited by 43
Wang, X., Wu, Y., Jiao, J., & Huang, Q. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.11.008 · Cited by 41
Wang, J., Ye, Q., Cao, Y., Guo, Y., Huang, X., Mi, W., Liu, S., Wang, C., Yang, H., Zhou, B. P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02243-3 · Cited by 40
“To determine whether HDAC also functions as a co-repressor of Snail in repression of 4E-BP1, we used an Food and Drug Administration-approved pan-HDAC inhibitor, vorinostat 37 , to test the potential effects of this inhibitor on modulation of 4E-BP1 expression and ef fi cacy of mTORkis.”
Lee, D. H., Won, H.-R., Ryu, H.-W., Han, J. M., & Kwon, S. H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4405 · Cited by 38
“HDAC inhibitors (HDACis) kill tumor cells via numerous mechanisms, including DNA repair inhibition, cell-cycle checkpoint disruption and the induction of apoptosis (28,29).”
Yano, M., Katoh, T., Miyazawa, M., Miyazawa, M., Ogane, N., Miwa, M., Hasegawa, K., Narahara, H., & Yasuda, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-38653-0 · Cited by 38
Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer
Zhang, J., Wang, Q., Wang, Q., Cao, J., Sun, J., & Zhu, Z. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03281-4 · Cited by 42
HDAC7 promotes the oncogenicity of nasopharyngeal carcinoma cells by miR-4465-EphA2 signaling axis
Li, Q., Xiao, T., Zhu, W., Yu, Z.-Z., Huang, X.-P., Yi, H. L., Lu, S., Tang, Y., Huang, W., & Xiao, Z. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2521-1 · Cited by 38
Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma
McGuire, J., Nerlakanti, N., Lo, C. H., Tauro, M., Utset‐Ward, T. J., Reed, D. R., & Lynch, C. C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33046 · Cited by 40
Histone deacetylases as targets in autoimmune and autoinflammatory diseases
Hamminger, P., Rîca, R., & Ellmeier, W. (2020) · Advances in immunology · doi:10.1016/bs.ai.2020.06.001 · Cited by 44
Kumbhar, N., Nimal, S., Barale, S. S., Kamble, S. A., Bavi, R., Sonawane, K. D., & Gacche, R. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-05698-7 · Cited by 41
Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
Salmon, J. M., Todorovski, I., Stanley, K. L., Bruedigam, C., Kearney, C. J., Martelotto, L. G., Rossello, F. J., Semple, T. J., Arnau, G. M., Zethoven, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1145 · Cited by 43
Self-citationSreenivasmurthy, S. G., Iyaswamy, A., Krishnamoorthi, S., Reddi, R. N., Kammala, A. K., Vasudevan, K., Senapati, S., Zhu, Z., Su, C.-F., Liu, J., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1030534 · Cited by 39
“Therefore, HDAC6 seems a valid pharmacological target for addressing tau pathology in AD (Falkenberg and Johnstone, 2014); (Passaro et al.”
BackgroundHistone 4 lysine 5/12 acetylation enables developmental plasticity of Pristionchus mouth form
Werner, M. S., Loschko, T., King, T., Reich, S., Theska, T., Franz‐Wachtel, M., Maček, B., & Sommer, R. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37734-z · Cited by 41
“Programmed cell death is one of several competing models by which TSA and other HDAC inhibitors have been proposed to underly antitumor effects in humans 42 – 44 .”
Mechanisms of HDACs in cancer development
Zhang, Y., Wang, H., Zhan, Z., Gan, L., & Bai, O. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1529239 · Cited by 71
Cancer Chemoradiotherapy Duo: Nano-Enabled Targeting of DNA Lesion Formation and DNA Damage Response
Jiang, W., Li, Q., Zhu, Z., Wang, Q., Dou, J., Zhao, Y., Lv, W., Zhong, F., Yao, Y., Zhang, G., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b10901 · Cited by 37
Nguyen, B. T., & Kang, M. (2019) · Molecules · doi:10.3390/molecules24101977 · Cited by 37
Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape
Farhy, C., Hariharan, S., Ylanko, J., Orozco, L., Zeng, F., Pass, I., Ugarte, F., Forsberg, E. C., Huang, C., Andrews, D. W., et al. (2019) · eLife · doi:10.7554/elife.49683 · Cited by 39
Discovery of highly potent HDAC8 PROTACs with anti-tumor activity
Zhao, C., Chen, D., Suo, F., Setroikromo, R., Quax, W. J., & Dekker, F. J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106546 · Cited by 41
Inhibitors of Histone Deacetylases Attenuate Noise-Induced Hearing Loss
Chen, J., Hill, K., & Sha, S. (2016) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-016-0567-7 · Cited by 38
Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation
Bellissimo, T., Ganci, F., Gallo, E., Sacconi, A., Tito, C., Angelis, L. D., Pulito, C., Masciarelli, S., Diso, D., Anile, M., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0655-2 · Cited by 37
Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation
Preglej, T., Hamminger, P., Luu, M., Bulat, T., Andersen, L., Göschl, L., Stolz, V., Rica, R., Sandner, L., Waltenberger, D., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133393 · Cited by 36
“Moreover, many nonhistone targets have been emerging, and HATs/HDACs function beyond the epigenetic control of gene expression (10–12).”
Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities
Zhang, Y., Remillard, D., Onubogu, U., Karakyriakou, B., Asiaban, J. N., Ramos, A. R., Bowland, K., Bishop, T. R., Barta, P. A., Nance, S., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01041-4 · Cited by 36
Liu, Y., Zhu, J., Jin, Y., Sun, Z., Wu, X., Zhou, H., & Yang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-58809-z · Cited by 46
“Consistent with data in mice, Entinostat treatment alone had limited effect in the hMHOs in regulating FXR activity and BA export (Fig.”
InfluentialMunkacsi, A. B., Hammond, N., Schneider, R. T., Senanayake, D., Higaki, K., Lagutin, K., Bloor, S. J., Ory, D. S., Maue, R. A., Chen, F. W., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.770578 · Cited by 39
Poly(N-(2-hydroxypropyl)methacrylamide)–valproic acid conjugates as block copolymer nanocarriers
Alfurhood, J. A., Sun, H. R., Kabb, C. P., Tucker, B. S., Matthews, J. H., Luesch, H., & Sumerlin, B. S. (2017) · Polymer Chemistry · doi:10.1039/c7py00196g · Cited by 36
Pidugu, V. R., Yarla, N. S., Bishayee, A., Kalle, A. M., & Satya, A. K. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1410-2 · Cited by 37
“HDAC8 belongs to class I HDACs [10] and is known to play a significant role in diverse physiological processes including cell cycle regulation [11], muscle contraction [12] and carcinogenesis [13].”
Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Cabrera, S. M., Engle, S., Kaldunski, M. L., Jia, S., Geoffrey, R., Simpson, P. M., Szabó, A., Speake, C., Greenbaum, C. J., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4708-x · Cited by 38
Yang, Z., Shen, M., Tang, M., Zhang, W., Cui, X. J., Zhang, Z., Pei, H., Li, Y., Hu, M., Bai, P., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.089 · Cited by 39
Liang, T., Qi, C., Lai, Y., Xie, J., Wang, H., Zhang, L., Lin, T., Jv, M., Li, J., Wang, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15772 · Cited by 37
Garcinol Is an HDAC11 Inhibitor
Son, S. I., Su, D., Ho, T. T., & Lin, H. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00719 · Cited by 36
Moreno–Yruela, C., Bæk, M., Vrsanova, A.-E., Schulte, C., Maric, H. M., & Olsen, C. A. (2021) · Nature Communications · doi:10.1038/s41467-020-20250-9 · Cited by 36
Rabal, O., José‐Eneriz, E. S., Agirre, X., Sánchez-Arias, J. A., de Miguel, I., Ordóñez, R., Gárate, L., Miranda, E., Sáez, E., Vilas‐Zornoza, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02255 · Cited by 38
Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer
Peng, Q., Li, H., Deng, Q., Liang, L., Wang, F., Lin, Y., Yang, L., Zhang, Y., Yu, X., & Zhang, L. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.06.066 · Cited by 38
Cytotoxic Effects of Valproic Acid on Neuroendocrine Tumour Cells
Arvidsson, Y., Johanson, V., Pfragner, R., Wängberg, B., & Nilsson, O. (2015) · Neuroendocrinology · doi:10.1159/000441849 · Cited by 36
KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL
Kurt, I. C., Sur‐Erdem, İ., Kaya-Aksoy, E., Cingöz, A., Kazancioglu, S., Kahya, Z., Toparlak, Ö. D., Senbabaoglu, F., Kaya, Z., Ozyerli‐Goknar, E., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.288 · Cited by 38
EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function
Bahl, S., Ling, H., Acharige, N. P. N., Santos‐Barriopedro, I., Pflum, M. K. H., & Seto, E. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03697-6 · Cited by 42
“Phosphotyrosine antibody cocktail (13-6620) was from Invitrogen (Thermo Fisher Scientific, Waltham, MA).”
MethodA Review of Machine Learning and Algorithmic Methods for Protein Phosphorylation Site Prediction
Esmaili, F., Pourmirzaei, M., Ramazi, S., Shojaeilangari, S., & Yavari, E. (2023) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2023.03.007 · Cited by 41
CRISPR Genome Engineering for Human Pluripotent Stem Cell Research
Chaterji, S., Ahn, E. H., & Kim, D.-H. (2017) · Theranostics · doi:10.7150/thno.18456 · Cited by 35
Wang, D. B., Kinoshita, C., Kinoshita, Y., Sopher, B. L., Uo, T., Lee, R. J., Kim, J. K., Murphy, S. P., Keene, C. D., Garden, G. A., et al. (2018) · Brain Pathology · doi:10.1111/bpa.12647 · Cited by 38
“HDAC inhibition mitigates a broad range of experimental neuropathological phenotypes associated with neurodegenerative diseases, traumatic brain injury, and ischemic stroke (8,24,30).”
BackgroundHwang, Y.-J., Na, J., Byun, S.-Y., Kwon, S., Yang, S. H., Lee, H.-S., Choi, H.-R., Cho, S., Youn, S. W., & Park, K. (2020) · Life · doi:10.3390/life10090157 · Cited by 36
Jankú, F., Park, H., Call, S. G., Madwani, K., Oki, Y., Subbiah, V., Hong, D. S., Naing, A., Velez-Bravo, V. M., Barnes, T. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1215 · Cited by 35
“Transaminitis 9 (41) 1 (5) 0 10 (45) 3 (17) 1 (6) 0 4 (22) 12 (30) 2 (5) 0 14 (35)”
BackgroundEpigenetic Mechanisms in Allergy Development and Prevention
Potaczek, D. P., Alhamwe, B. A., Miethe, S., & Garn, H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_475 · Cited by 38
Xu, J., Mao, J., Han, X. M., Shi, F., Gao, Q. F., Wang, T., Zhang, Z., Shan, Y., Fang, W., & Li, X. (2021) · Journal of Virology · doi:10.1128/jvi.00853-21 · Cited by 36
Chen, Y., Lu, C.-H., Ke, C., Chiu, S.-J., Chang, C., Yang, B., Gelovani, J. G., & Liu, R.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168633 · Cited by 34
Makki, M. S., & Haqqi, T. M. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.06.010 · Cited by 39
Barter, M. J., Butcher, A., Wang, H., Tsompani, D., Galler, M., Rumsby, E. L., Culley, K. L., Clark, I. M., & Young, D. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-10518-z · Cited by 35
Chemically induced degradation of epigenetic targets
Kabir, M., Yu, X., Kanıskan, H. Ü., & Jin, J. J. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00100h · Cited by 38
Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases
Christianson, D. W. (2024) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00801 · Cited by 37
D’Amato, L., Dell’Aversana, C., Conte, M., Ciotta, A., Scisciola, L., Carissimo, A., Nebbioso, A., & Altucci, L. (2014) · Epigenetics · doi:10.4161/15592294.2014.988035 · Cited by 37
Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay
Hsu, C.-W., Shou, D., Huang, R., Khuc, T., Dai, S., Zheng, W., Klumpp-Thomas, C. A., & Xia, M. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116629381 · Cited by 37
Assessment of HDACi-Induced Cytotoxicity
Marx-Blümel, L., Marx, C., Kühne, M., & Sonnemann, J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6527-4_3 · Cited by 34
Wu, Y.-W., Hsu, K., Lee, H., Huang, T., Lin, T. E., Chen, Y., Sung, T.-Y., Liou, J., Hwang‐Verslues, W. W., Pan, S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00205 · Cited by 35
“Molecular docking analysis of MPT0B451 and HDAC6 showed common features with traditional HDAC inhibitors Frontiers in Pharmacology | www.frontiersin.org 9 March 2018 | Volume 9 | Article 205 (Falkenberg and Johnstone, 2014).”
BackgroundMethodHDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal
Rossi, L., Battistelli, C., de Turris, V., Noce, V., Zwergel, C., Valente, S., Moioli, A., Manzione, A., Palladino, M., Bordoni, V., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26319-2 · Cited by 38
Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease
Bodas, M., & Vij, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00020 · Cited by 37
“, 2015), cancer (Falkenberg and Johnstone, 2014; West and Johnstone, 2014; De Souza and Chatterji, 2015), graft-versus-host disease (Choi et al.”
Gurbani, S. S., Yoon, Y., Weinberg, B. D., Salgado, E., Press, R. H., Cordova, J. S., Ramesh, K. K., Liang, Z., Vega, J. E. V., Voloschin, A. D., et al. (2019) · Tomography · doi:10.18383/j.tom.2018.00031 · Cited by 35
“Both arms showed similar distributions of known genetic targets that improve response to radiation—mutation of isocitrate dehydrogenase 1 (IDH1) and promoter methylation of the gene for O (6)-methylguanine-DNA methyltransferase (24).”
BackgroundOuyang, B., Chen, D., Hou, X., Wang, T., Wang, J., Zou, W., Song, Z., Huang, C., Guo, Q., & Weng, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00346 · Cited by 37
Wolff, B., Jänsch, N., Sugiarto, W. O., Frühschulz, S., Lang, M., Altintas, R., Oehme, I., & Meyer‐Almes, F. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111756 · Cited by 34
Srivastava, A., Banerjee, J., Dubey, V., Tripathi, M., Chandra, P. S., Sharma, M. C., Lalwani, S., Siraj, F., Doddamani, R. S., & Dixit, A. B. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00994-0 · Cited by 37
Borgonetti, V., & Galeotti, N. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105431 · Cited by 35
Lin, Y., Li, S., Xiao, Z., Chen, S., Yang, L., Peng, Q., Li, H., Fu, J., Yu, X., & Zhang, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105787 · Cited by 35
Jiang, B., Hu, J., Liu, H., Liu, Z., Wen, Y., Liu, M., Zhang, H., Pang, X., & Yu, L.-F. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113893 · Cited by 34
Sodium butyrate-induced apoptosis and ultrastructural changes in MCF-7 breast cancer cells
Wang, Y., Hu, P., Ma, Y., Fan, R., Gao, F., Zhang, J., & Wei, L. (2016) · Ultrastructural Pathology · doi:10.3109/01913123.2016.1170083 · Cited by 34
Ali, D., Hamam, R., Al-Fayez, M., Kassem, M. S., Aldahmash, A. M., & Alajez, N. M. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0331 · Cited by 37
Panella, S., Marcocci, M. E., Celestino, I., Valente, S., Zwergel, C., Puma, D. D. L., Nencioni, L., Mai, A., Palamara, A. T., & Simonetti, G. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0073 · Cited by 38
Lee, P. W. T., Koseki, L. R., Haitani, T., Harada, H., & Kobayashi, M. (2024) · Cancers · doi:10.3390/cancers16091729 · Cited by 42
“Nonetheless, the progress towards clinical application for the treatment of solid tumors is rather limited to date [199,200], as adverse outcomes, which can be exemplified by the low efficacy accompanied by significant toxicity in urothelial cancer and exacerbated metastasis in breast cancer, have…”
BackgroundOverview of class I HDAC modulators: Inhibitors and degraders
Huang, Z., Zeng, L., Cheng, B., & Li, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116696 · Cited by 36
Mohamed, M. F. A., Salem, I. M., Fouad, A. M., Allam, R. M., Fadaly, W. A. A., Nemr, M. T. M., Ewieda, S. Y., Ibrahim, T. S., Ibrahim, N. A., & Abou-Salim, M. A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108694 · Cited by 36
Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer
Zhao, J., Gray, S. G., Greene, C. M., & Lawless, M. W. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1568870 · Cited by 36
Liu, S., Zhang, K., Zhu, Q., Shen, Q., Zhang, Q., Yu, J., Chen, Y., & Lu, W. P. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.046 · Cited by 33
Mao, J., Li, S., Zhao, H., Zhu, Y., Hong, M., Zhu, H., Qian, S., & Li, J. (2018) · Europe PMC (PubMed Central) · Cited by 33
Zhang, J., Peng, J., Huang, Y., Meng, L. H., Li, Q., Xiong, F., & Li, X. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202001205 · Cited by 34
Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms
Wu, L., Ye, K., Jiang, S., & Zhou, G. (2021) · Marine Drugs · doi:10.3390/md19090488 · Cited by 36
“HDACs are responsible for the deacetylation of lysine residues in histone and non-histone proteins, leading to chromatin condensation and transcriptional repression [99].”
BackgroundEpigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?
Avcı, E., Sarvari, P., Savai, R., Seeger, W., & Pullamsetti, S. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010546 · Cited by 37
“Targeting HDACs in an isoform-specific manner could achieve enhanced clinical utility by reducing or eliminating the serious side effects associated with current first-generation non-selective HDAC inhibitors [149,150].”
BackgroundRoles and regulation of histone acetylation in hepatocellular carcinoma
Xia, J., Qin, X.-Q., Zhang, L., Liu, S., Shi, X., & Ren, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.982222 · Cited by 35
“Conversely, HDACs erase the acetyl groups from the lysine residues located on N-terminal ends of histone proteins and recover the positive charge of lysine, resulting in a closed state of chromatin and silencing gene expression (Gray and Dangond, 2006; Falkenberg and Johnstone, 2014; Ganai, 2020c).”
BackgroundMensah, A. A., Kwee, I., Gaudio, E., Rinaldi, A., Ponzoni, M., Cascione, L., Fossati, G., Stathis, A., Zucca, E., Caprini, G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3239 · Cited by 41
Xie, R., Yao, Y., Tang, P., Chen, G., Liu, X., Yun, F., Cheng, C., Wu, X., & Yuan, Q. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.038 · Cited by 34
Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy
Wang, Z., Wu, D., Zhao, X., Liu, C., Jia, S., He, Q., Huang, F., Cheng, Z., Lu, T., Chen, Y., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115759 · Cited by 33
Understanding the Complexity of Epigenetic Target Space
Pande, V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01507 · Cited by 40
Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
Wang, Y., Wallach, J. V., Duane, S., Wang, Y., Wu, J., Wang, J., Adejare, A., & Ma, H. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s124977 · Cited by 33
Rafehi, H., Kaspi, A., Ziemann, M., Okabe, J., Karagiannis, T. C., & El‐Osta, A. (2017) · Epigenetics · doi:10.1080/15592294.2017.1371892 · Cited by 33
“Although early work focused almost exclusively on antineoplastic properties, HDACi are now being investigated for a host of non-oncological applications that are driven, at least in part, by their potent anti-inflammatory effects.(15) For example, pre-clinical models show that HDAC treatment attenuates cardiac hypertr…”
BackgroundWang, X., Jiang, X., Sun, S., & Liu, Y. (2018) · RSC Advances · doi:10.1039/c8ra02578a · Cited by 34
Porter, N. J., Shen, S., Bařinka, C., Kozikowski, A. P., & Christianson, D. W. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00487 · Cited by 33
Bhat, J., Dubin, S., Dananberg, A., Quabius, E. S., Fritsch, J., Dowds, C. M., Saxena, A., Chitadze, G., Lettau, M., & Kabelitz, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00569 · Cited by 32
“On the other hand, histone deacetylases (HDAC) are epigenetic erasers, which remove such marks (11).”
BackgroundKhoueiry, P., Gahlawat, A. W., Petretich, M., Michon, A., Simola, D. F., Lam, E. Y. N., Furlong, E. E. M., Beneš, V., Dawson, M. A., Prinjha, R. K., et al. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0286-5 · Cited by 38
Roles of Histone Acetylation Modifiers and Other Epigenetic Regulators in Vascular Calcification
Kwon, D., Ryu, J., Kim, Y., & Kook, H. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093246 · Cited by 34
“However, studies of HDAC inhibitors in VC and CVDs are still in preclinical phases.”
BackgroundInfluentialLysine Acetyltransferase Inhibitors From Natural Sources
Fiorentino, F., Mai, A., & Rotili, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01243 · Cited by 33
“The targets of the acetylation/deacetylation reaction include different classes of proteins such as enzymes (for instance kinases), transcription factors, and histones (Falkenberg and Johnstone, 2014; Carafa et al., 2016; Fiorentino et al., 2018).”
BackgroundHDAC3i‐Finder: A Machine Learning‐based Computational Tool to Screen for HDAC3 Inhibitors
Li, S., Ding, Y., Chen, M., Chen, Y., Kirchmair, J., Zhu, Z., Wu, S., & Xia, J. (2020) · Molecular Informatics · doi:10.1002/minf.202000105 · Cited by 33
Wan, G., Feng, Z., Zhang, Q., Li, X., Ran, K., Feng, H., Luo, T.-W., Zhou, S., Su, C., Wei, W., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01413 · Cited by 33
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.